Evidence map›Paper›PMID 26528782›Full record

ArticleCurrent protocols in microbiology2015

Generation of Recombinant Vaccinia Viruses.

Linda S Wyatt, Patricia L Earl, Bernard Moss

Abstract read
In one paragraph

Article in Current protocols in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Linda S WyattNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Patricia L EarlNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Bernard MossNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

Funding

Recombinant Virus VaccinesZIAAI000416 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOSS, BERNARD · 2009 to 2025
$17.3M
Intramural NIH HHS ZIA AI000416
6 · The paper itself

Abstract

This unit describes how to infect cells with vaccinia virus and then transfect them with a plasmid-transfer vector or PCR fragment to generate a recombinant virus. Selection and screening methods used to isolate recombinant viruses and a method for the amplification of recombinant viruses are described. Finally, a method for live immunostaining that has been used primarily for detection of recombinant modified vaccinia virus Ankara (MVA) is presented.

Indexed as

Recombination, GeneticGenetic TestingImmunologic TechniquesMolecular BiologySelection, GeneticStaining and LabelingTransfectionVaccinia virusVirologyVirus Cultivation

Identifiers

PMID26528782
PMCPMC5123791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.